

Retinal Vein Occlusion - Pipeline Review, H1 2020

<https://marketpublishers.com/r/R1DD982BED6EN.html>

Date: June 2020

Pages: 93

Price: US\$ 2,000.00 (Single User License)

ID: R1DD982BED6EN

Abstracts

Retinal Vein Occlusion - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2020, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 5, 2, 6 and 2 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Retinal Vein Occlusion - Overview
- Retinal Vein Occlusion - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Retinal Vein Occlusion - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Retinal Vein Occlusion - Companies Involved in Therapeutics Development
 - 3SBio Inc
 - Addmedica SAS
 - Annexin Pharmaceuticals AB
 - Calpain Therapeutics Pty Ltd
 - Chengdu Kanghong Pharmaceuticals Group Co Ltd
 - Drive Therapeutics LLC
 - EyePoint Pharmaceuticals Inc
 - Gene Signal International SA
 - Graybug Vision Inc
 - Kodiak Sciences Inc
 - Kuur Therapeutics Ltd
 - Lupin Ltd
 - Novartis AG
 - Ocular Therapeutix Inc
 - Outlook Therapeutics Inc
 - Panoptes Pharma GesmbH
 - Regeneron Pharmaceuticals Inc
 - Ripple therapeutics Corp
- Retinal Vein Occlusion - Drug Profiles
 - aflibercept biosimilar - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - aflibercept SR - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
aganirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANXV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brolocizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-28P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

KSI-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LKA-651 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit VEGF for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CAPN1 and CAPN2 for Ischaemic Retinal Vein Occlusion -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vorolanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinal Vein Occlusion - Dormant Projects

Retinal Vein Occlusion - Discontinued Products

Retinal Vein Occlusion - Product Development Milestones

Featured News & Press Releases

Feb 08, 2020: Kodiak Sciences announces additional safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in patients with wet age-related macular

degeneration, diabetic macular edema and retinal vein occlusion at the angiogenesis, exudation, and degeneration 2020 meeting

Feb 05, 2020: Kodiak Sciences announces upcoming presentation of additional KSI-301 phase 1b clinical study data at Angiogenesis, Exudation, and Degeneration 2020 meeting

Oct 11, 2019: Kodiak Sciences announces safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

Oct 07, 2019: Kodiak Sciences announces upcoming presentation of durability data from clinical development program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

Oct 02, 2019: Graybug Vision initiates Phase 2b (ALTISSIMO) clinical trial of GB-102 in patients with Wet Age-Related Macular Degeneration

Sep 18, 2019: Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

Sep 04, 2019: Kodiak Sciences announces upcoming presentations at EURETINA Meeting

Jul 29, 2019: Kodiak's anti-VEGF antibody yields positive data in Phase Ib study

Jul 24, 2019: Kodiak Sciences announces upcoming presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting

Apr 24, 2019: Interface Biologics to present local drug delivery technology update at Bloom Burton & Co. Healthcare Investor Conference

Feb 08, 2019: Kodiak Sciences announces upcoming presentation of KSI-301 12-week phase 1a study data at Angiogenesis, Exudation, and Degeneration 2019 Meeting

Dec 21, 2018: Kodiak Sciences announces completion of 12-week phase 1a study of KSI-301 in patients with diabetic macular edema demonstrating safety and durability of responses following single dose of intravitreal anti-VEGF antibody biopolymer conjugate

Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Retinal Vein Occlusion, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Retinal Vein Occlusion - Pipeline by 3SBio Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2020

Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H1 2020

Retinal Vein Occlusion - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020

Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020

Retinal Vein Occlusion - Pipeline by Drive Therapeutics LLC, H1 2020

Retinal Vein Occlusion - Pipeline by EyePoint Pharmaceuticals Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H1 2020

Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Kodiak Sciences Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Kuur Therapeutics Ltd, H1 2020

Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2020

Retinal Vein Occlusion - Pipeline by Novartis AG, H1 2020

Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Outlook Therapeutics Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Panoptes Pharma GesmbH, H1 2020

Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Retinal Vein Occlusion - Pipeline by Ripple therapeutics Corp, H1 2020

Retinal Vein Occlusion - Dormant Projects, H1 2020

Retinal Vein Occlusion - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Retinal Vein Occlusion, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc

Addmedica SAS

Annexin Pharmaceuticals AB

Calpain Therapeutics Pty Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Drive Therapeutics LLC

EyePoint Pharmaceuticals Inc

Gene Signal International SA

Graybug Vision Inc

Kodiak Sciences Inc

Kuur Therapeutics Ltd

Lupin Ltd

Novartis AG

Ocular Therapeutix Inc

Outlook Therapeutics Inc

Panoptes Pharma GesmbH

Regeneron Pharmaceuticals Inc

Ripple therapeutics Corp

I would like to order

Product name: Retinal Vein Occlusion - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/R1DD982BED6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R1DD982BED6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970